GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (FRA:RFS) » Definitions » Other Liabilities for Insurance Companies

Resverlogix (FRA:RFS) Other Liabilities for Insurance Companies


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Other Liabilities for Insurance Companies?

Other Liabilities for Insurance Companies only applies to insurance companies.


Resverlogix (FRA:RFS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (FRA:RFS) » Definitions » Other Liabilities for Insurance Companies
Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.